Sale!

TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The TBP Gene Spinocerebellar Ataxia Type 17 (SCA17) Autosomal Dominant Genetic Test is a specialized diagnostic procedure aimed at detecting mutations in the TBP gene, which are responsible for causing SCA17. This condition is a form of spinocerebellar ataxia characterized by progressive degeneration of the cerebellum and other regions of the brain, leading to symptoms such as uncoordinated movements, balance problems, and difficulties with speech. The test is crucial for individuals with a family history of SCA17 or those exhibiting symptoms, as it helps in confirming the diagnosis, enabling early intervention and management strategies.

Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient’s DNA sample, typically obtained from a blood draw, to identify the specific trinucleotide repeat expansion in the TBP gene that causes SCA17. The presence of an abnormal number of repeats confirms the diagnosis of SCA17.

The cost of the TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated nature of the testing process, including the use of advanced genetic sequencing technologies and the expertise required to interpret the results accurately. For individuals at risk, this test provides invaluable information that can guide treatment decisions and genetic counseling, offering insights into the likelihood of passing the condition on to future generations.

Description

TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test

Test Name: TBP Gene Spinocerebellar Ataxia Type 17 Autosomal Dominant Genetic Test

Components: Blood or Extracted DNA or One drop Blood on FTA Card

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for TBP Gene Spinocerebellar Ataxia Type 17, Autosomal Dominant NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with TBP Gene Spinocerebellar Ataxia Type 17, Autosomal Dominant.

Test Details: Spinocerebellar Ataxia Type 17 (SCA17) is a rare neurodegenerative disorder characterized by progressive ataxia, which is the lack of muscle coordination, and other neurological symptoms. It is caused by a mutation in the TBP gene, which is involved in the regulation of gene expression. An autosomal dominant NGS genetic test for SCA17 refers to a Next-Generation Sequencing (NGS) test that analyzes the TBP gene to identify mutations or variants that may be associated with SCA17. This type of genetic test can help confirm a diagnosis of SCA17 in individuals who have symptoms of the condition and may also be used for carrier testing in individuals with a family history of SCA17. NGS technology allows for the simultaneous analysis of multiple genes, making it a powerful tool for genetic testing. In the case of SCA17, the NGS test would specifically focus on sequencing the TBP gene to identify any disease-causing mutations or variants. The test typically involves collecting a blood or saliva sample from the individual, which is then sent to a laboratory for analysis. The laboratory will use NGS technology to sequence the TBP gene and compare the results to a reference sequence to identify any genetic variations. It is important to note that a positive genetic test result for SCA17 does not necessarily mean that an individual will develop symptoms of the condition. The onset and severity of symptoms can vary widely among affected individuals, even within the same family. Genetic testing can, however, provide valuable information for diagnosis, prognosis, and family planning purposes. Genetic counseling is often recommended both before and after genetic testing to help individuals understand the implications of the test results and make informed decisions.

Test Name	TBP Gene Spinocerebellar ataxia type 17 autosomal dominant Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Neurological Disorders
Doctor	Neurologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for TBP Gene Spinocerebellar ataxia type 17, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with TBP Gene Spinocerebellar ataxia type 17, autosomal dominant
Test Details	Spinocerebellar ataxia type 17 (SCA17) is a rare neurodegenerative disorder characterized by progressive ataxia, which is the lack of muscle coordination, and other neurological symptoms. It is caused by a mutation in the TBP gene, which is involved in the regulation of gene expression. An autosomal dominant NGS genetic test for SCA17 refers to a Next-Generation Sequencing (NGS) test that analyzes the TBP gene to identify mutations or variants that may be associated with SCA17. This type of genetic test can help confirm a diagnosis of SCA17 in individuals who have symptoms of the condition and may also be used for carrier testing in individuals with a family history of SCA17. NGS technology allows for the simultaneous analysis of multiple genes, making it a powerful tool for genetic testing. In the case of SCA17, the NGS test would specifically focus on sequencing the TBP gene to identify any disease-causing mutations or variants. The test typically involves collecting a blood or saliva sample from the individual, which is then sent to a laboratory for analysis. The laboratory will use NGS technology to sequence the TBP gene and compare the results to a reference sequence to identify any genetic variations. It is important to note that a positive genetic test result for SCA17 does not necessarily mean that an individual will develop symptoms of the condition. The onset and severity of symptoms can vary widely among affected individuals, even within the same family. Genetic testing can, however, provide valuable information for diagnosis, prognosis, and family planning purposes. Genetic counseling is often recommended both before and after genetic testing to help individuals understand the implications of the test results and make informed decisions.